Lymphomatoid Papulosis: A T-Cell Dyscrasia with a Propensity To Transform into Malignant Lymphoma

Cabanillas, Fernando; Armitage, Jamés O.; Pugh, William; Weisenburger, Dennis D.; Duvic, Madeleine

doi:10.7326/0003-4819-122-3-199502010-00009

Cited by 83 publications

(47 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The skin lesions spontaneously involuted within five months and then recurrences appeared on other sites. 3,4 . LyP is characterized by cyclic eruptions of erythematous papulonodular lesions that are usually ＜10 mm in size with occasional central ulceration, and this is followed by spontaneous healing and scar formation.…”

Section: Case Reportmentioning

confidence: 99%

CD8+ Lymphomatoid Papulosis

Sim

Kim

2011

Ann Dermatol

View full text Add to dashboard Cite

Section: Case Reportmentioning

confidence: 99%

CD8+ Lymphomatoid Papulosis

Sim

Kim

2011

Ann Dermatol

View full text Add to dashboard Cite

“…In comparison, absolute frequencies between 5% and 24% have been reported in the literature [3][4][5][6][7][8][9][10] (Table 2). However, rather than calculating the absolute frequency in a given LyP patient cohort, an analysis of the course of the disease indicates that there is a considerably increased risk for progression when LyP is followed up for extended time periods (Table 3).…”

mentioning

confidence: 99%

Prognosis of Lymphomatoid Papulosis

et al. 2006

View full text Add to dashboard Cite

“…Other studies have contradicted this low rate of evolution to lymphoma. One study, for instance, found that 25% of patients with LP developed PCALCL, systemic ALCL, other T-cell lymphomas, or Hodgkin's disease (HD) [16]. That study was small, however, and selection bias may have accounted for the higher rate of lymphoma in that series.…”

Section: Epidemiology and Clinical Presentationmentioning

confidence: 95%

Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type

Jacobsen

2006

The Oncologist

View full text Add to dashboard Cite

Anaplastic large-cell lymphoma, T-/null-cell type (ALCL), is a rare disease that has only been well characterized for two decades. Despite this, the biology of ALCL is better understood than that of many other more common variants of lymphoma. This review focuses on the pathophysiology, clinical presentation, and therapy of ALCL, including stem cell transplantation. In particular, the text emphasizes how novel prognostic features and the evolving understanding of the biology of this disease will influence treatment selection and drug development. The Oncologist 2006;11:831-840 Epidemiology and Clinical PresentationAnaplastic large-cell lymphoma, T-/null-cell type (ALCL), is a rare disease, accounting for <5% of all cases of nonHodgkin's lymphoma (NHL) [1]. ALCL was first described as a clinical entity in 1985 based upon its unique characteristic of cohesive proliferation of large pleomorphic cells expressing CD 30 (Ki-1) [2]. ALCL has a peak incidence in childhood and accounts for approximately 40% of NHL cases diagnosed in pediatric populations [3]. There appears to be a male predominance, particularly in anaplastic lymphoma kinase (ALK) + cases, in which the male/female ratio is approximately 3:1. In one series, the male predominance of ALK + cases was especially striking in patients under the age of 30, with a male/female ratio of 6.5:1 [4].There are no clear risk factors for developing ALCL. Some reports have suggested that Epstein-Barr virus (EBV) is important in the pathogenesis of ALCL. However, a recent series of 64 ALCL cases revealed no EBVencoded RNA (EBER) or immunohistochemistry evidence for EBV-latent membrane protein type 1 [5]. The authors concluded that previous reports of EBV in Western patients with ALCL were probably a result of the inclusion of tumors no longer considered to be ALCL, such as CD30 + anaplastic tumors of B-cell origin. EBV, however, may be important in the pathogenesis of ALCL occurring in Asia and in immune-compromised hosts [6, 7].ALCL occurs as two distinct clinical entities, a cutaneous and a systemic variant [8]. Cutaneous ALCL falls under Learning ObjectivesAfter completing this course, the reader will be able to:1. Identify areas of diagnostic confusion in anaplastic large-cell lymphoma (ALCL).2. Describe risk stratification in ALCL. Discuss therapeutic options in ALCL.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME + lymphoproliferative disorders of the skin that represents a spectrum of disease ranging from the benign lymphomatoid papulosis (LP) to the malignant primary cutaneous ALCL (PCALCL) [9]. Both PCALCL and LP generally occur in older adults and are rare in children [10]. LP resembles lymphoma and is essentially indistinguishable from PCALCL histologically [11]. Thus the distinction between the two disorders is largely clinical.Patients with LP tend to have more diffuse lesions, whereas PCALCL is more likely to be solitary [12]. LP lesions are generally <3 cm, whereas PCALCL lesions are ...

show abstract

Lymphomatoid Papulosis: A T-Cell Dyscrasia with a Propensity To Transform into Malignant Lymphoma

Cited by 83 publications

References 0 publications

CD8+ Lymphomatoid Papulosis

CD8+ Lymphomatoid Papulosis

Prognosis of Lymphomatoid Papulosis

Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type

Contact Info

Product

Resources

About